Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Salcaprozic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 known ✓ | P09917 | 3/20 | 0.60 |
| ▸ | NAAA | Q02083 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.58 |
| ▸ | NAMPT | P43490 | 1/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ESRRG | P62508 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salcaprozic Acid SCHEMBL29509907 | 1.00 | NAAA (0.67) | NAAAALOX5HTTALDH1A1TSHR | |
| SCHEMBL253212 | 1.00 | NAAA (0.67) | NAAAALOX5HTTALDH1A1TSHR | |
| Salcaprozic Acid SCHEMBL20511604 | 1.00 | NAAA (0.67) | NAAAALOX5HTTALDH1A1TSHR | |
| SCHEMBL2331877 | 1.00 | NAAA (0.67) | NAAAALOX5HTTALDH1A1TSHR | |
| Salcaprozic Acid SCHEMBL26908047 | 0.97 | NAAA (0.67) | NAAAALOX5HTTALDH1A1TSHR | |
| Alcohol SCHEMBL2331970 | 0.95 | NAAA (0.68) | NAAAALOX5HTTALDH1A1TSHR | |
| SCHEMBL4956771 | 0.94 | TSHR (0.61) | NAAAALOX5HTTALDH1A1TSHR | |
| Salcaprozic Acid SCHEMBL29036081 | 0.90 | NAAA (0.65) | NAAAALOX5HTTALDH1A1TSHR | |
| Salcaprozic Acid SCHEMBL29036010 | 0.90 | NAAA (0.65) | NAAAALOX5HTTALDH1A1TSHR | |
| SCHEMBL823552 | 0.87 | NAAA (0.84) | NAAAALOX5HTTALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1486 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743069-A1 | STABLE SOLID DISPERSIONS OF SALCAPROZATE WITH VARIOUS ACTIVE PHARMACEUTICAL INGREDIENTS | Biophore India Pharmaceuticals Pvt. Ltd. (IN) | 2026-05-20 | — | — | EP | claimed |
| WO-2026098581-A1 | PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR | 深圳奥礼生物科技有限公司 | 2026-05-15 | — | — | WO | claimed |
| WO-2026099117-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1 ANALOG AND AN INORGANIC MESOPOROUS MATERIAL | MERCK PATENT GMBH (DE) | 2026-05-15 | — | — | WO | claimed |
| CN-120189496-B | Oral polypeptide composition | 深圳奥礼生物科技有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| EP-4736844-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1 ANALOG AND AN INORGANIC MESOPOROUS MATERIAL | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-12616738-B2 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid | NOVO NORDISK A/S (DK) | 2026-05-05 | — | — | US | claimed |
| EP-4731236-A1 | SEMAGLUTIDE IN MEDICAL THERAPY | Novo Nordisk A/S (DK) | 2026-04-29 | — | — | EP | claimed |
| US-12611431-B2 | Approach to sustained production and delivery of nitric oxide and S-nitrosothiols | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2026-04-28 | — | — | US | claimed |
| US-12605332-B2 | Transdermal delivery formulations | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2026-04-21 | — | — | US | claimed |
| EP-3256149-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | Entera Bio Ltd. (IL) | 2017-12-20 | — | — | EP | claimed |
| EP-3256113-A1 | TREATMENT OF HYPOPARATHYROIDISM | Entera Bio Ltd. (IL) | 2017-12-20 | — | — | EP | claimed |
| EP-3256153-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS WITH CONTROLLED ABSORPTION PROFILE | Entera Bio Ltd. (IL) | 2017-12-20 | — | — | EP | claimed |
| WO-2016128972-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS WITH CONTROLLED ABSORPTION PROFILE | ENTERA BIO LTD. (IL) | 2016-08-18 | — | — | WO | claimed |
| WO-2016128973-A1 | TREATMENT OF OSTEOPOROSIS | ENTERA BIO LTD. (IL) | 2016-08-18 | — | — | WO | claimed |
| WO-2016128970-A1 | TREATMENT OF HYPOPARATHYROIDISM | ENTERA BIO LTD. (IL) | 2016-08-18 | — | — | WO | claimed |
| WO-2016128974-A1 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ENTERA BIO LTD. (IL) | 2016-08-18 | — | — | WO | claimed |
| WO-2016128971-A1 | TREATMENT OF BONE FRACTURES AND DEFECTS | ENTERA BIO LTD. (IL) | 2016-08-18 | — | — | WO | claimed |
| US-8962554-B2 | Oral insulin therapies and protocol | EMISPHERE TECHNOLOGIES, INC. (US) | 2015-02-24 | — | — | US | claimed |
| US-20140206612-A1 | ORAL INSULIN THERAPIES AND PROTOCOL | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-07-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206612-A1 | ORAL INSULIN THERAPIES AND PROTOCOL | IAPP, GPR119, GCG | ALOX5 1865/4885NAAA 3516/4885HTT 1021/4885 |
| US-12611431-B2 | Approach to sustained production and delivery of nitric oxide and S-nitrosothiols | NOS2, NOS1, PTGIS | ALOX5 1056/4885NAAA 2179/4885HTT 1289/4885 |
| US-12616738-B2 | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid | SLC5A1, GLP1R, SLC5A2 | ALOX5 3897/4885NAAA 369/4885HTT 214/4885 |
| US-12605332-B2 | Transdermal delivery formulations | NOS1, NOS2, VDR | ALOX5 218/4885NAAA 3811/4885HTT 2768/4885 |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | GLP1R, TTR, IAPP | ALOX5 3826/4885NAAA 3846/4885HTT 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.